Related Experiment Video
Updated: Jun 2, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Long-term follow-up in patients with presumptive Brugada syndrome treated with implanted defibrillators
Daniel Steven1, Kurt C Roberts-Thomson, Keiichi Inada
1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. dsteven@uke.de
Insights
Risk stratification for Brugada syndrome (BS) is challenging. For patients without prior cardiac arrest, adverse effects from implantable cardioverter-defibrillators (ICDs) may outweigh the benefits of arrhythmia protection.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Devices
Background:
- Brugada syndrome (BS) risk stratification is difficult.
- Implantable cardioverter-defibrillators (ICDs) offer arrhythmia protection for high-risk patients.
Purpose of the Study:
- To evaluate the outcomes and complications of ICD implantation in patients with suspected Brugada syndrome.
Main Methods:
- Retrospective review of 33 patients with suspected Brugada syndrome who underwent ICD implantation between 1995 and 2008.
- Analysis of patient demographics, BS type, electrophysiology study findings, and long-term follow-up data.
Main Results:
- The study included 30 men and 3 women, with Type I Brugada observed in 54.5% of patients.
- During a mean follow-up of 7.9 years, only 2 patients with prior cardiac arrest received appropriate ICD shocks.
- Adverse effects occurred in 33% of patients, including inappropriate shocks (15%) and major device-related complications (24%).
Conclusions:
- Risk stratification for primary prevention in Brugada syndrome remains challenging.
- The low incidence of arrhythmic events in patients without prior cardiac arrest suggests that ICD-related adverse effects may exceed the benefits.
- Discussions regarding ICD implantation should carefully consider the risk-benefit profile for patients without a history of cardiac arrest.
Introduction:
Risk stratification for patients with suspected Brugada syndrome (BS) remains difficult. Implantation of cardioverter-defibrillators (ICDs) in high-risk patients provides continuous long-term arrhythmia protection.
Methods:
Data of 33 consecutive patients undergoing ICD implantation after BS evaluation between 1995 and 2008 were reviewed.
Results:
There were 30 (91%) men and 3 (9%) women (46.4 ± 11.7 years). Type I Brugada was noted in 18 (54.5%), type II in 12 (36.4%) patients, and ST elevation after drug challenge in 3 patients (9.1%). Three patients had prior cardiac arrest; 70% a history of syncope; and 56% ventricular arrhythmias at the electrophysiology study. During 7.9 ± 3.6 years of follow-up, 2 patients with prior arrest received appropriate ICD shocks. None of the 30 patients without prior arrest had a sustained arrhythmia detected. ICD-related adverse effects occurred in 11 (33%) patients, including inappropriate shocks in 5 (15%). Eight patients (24%) developed 11 major device-related complications including subclavian vein thrombosis (1), pericardial effusion (1), lead fracture (2), and infection (2); in 4 patients the only complication was premature battery depletion that required early ICD replacement; however, some of these complications such as lead fractures and early battery depletion may not be specific for this patient cohort and may not repeat in the future.
Conclusion:
Risk stratification for patients with BS for primary prevention remains challenging. The low risk of arrhythmic events that is exceeded by ICD-related adverse effects should inform discussions with patients who do not have a prior history of cardiac arrest.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Endocarditis III: Medical Management
Cardiomyopathy II: Dilated Cardiomyopathy
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac muscle...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
